Recently, the risk of ovarian malignancy algorithm (ROMA) score, a combination of CA125, HE4, and the menopausal status of patients, has been used for diagnosing and assessing the prognosis of ovarian cancer with a high sensitivity and specificity (Moore et al., 2009). This evidence concerns the gene MUC16 and ovarian carcinoma.